Although the factors responsible for the recent increase in the prevalence of diabetes worldwide are not entirely known, the morbidity associated with this disease results in substantial health and economic burden on society. Epigenetic modifications, including DNA methylation have been identified as one mechanism by which the environment interacts with the genome and there is evidence that alterations in DNA methylation may contribute to the increased prevalence of both type 1 and type 2 diabetes. This review provides a summary of DNA methylation and its role in gene regulation, and includes descriptions of various techniques to measure site-specific and genome-wide DNA methylation changes. In addition, we review current literature highlighting the complex relationship between DNA methylation, gene expression, and the development of diabetes and related complications. In studies where both DNA methylation and gene expression changes were reported, DNA methylation status had a strong inverse correlation with gene expression, suggesting that this interaction may be a potential future therapeutic target. We highlight the emerging use of genome-wide DNA methylation profiles as a biomarker to predict patients at risk of developing diabetes or specific complications of diabetes. The development of a predictive model that incorporates both genetic sequencing and DNA methylation data may be an effective diagnostic approach for all types of diabetes and could lead to additional innovative therapies.
epigenetic modifications describes changes in DNA methylation, changes in the acetylation, methylation, or phosphorylation of histones as well as changes in non-coding RNA expression that are not related to changes in DNA sequence, but are mitotically heritable alterations that can ultimately influence gene expression. However, recent studies have suggested that genetic and epigenetic modes of inheritance may be even more complex than initially thought. For instance, studies suggesting that DNA polymorphisms may result in specific genomic regions that are more or less receptive to epigenetic marks, [11] [12] [13] thus indicating that epigenetic modifications can be influenced by genetic sequence variations. In addition, environmental factors such as diet, stress, physical activity, and a suboptimal in utero environment can alter the epigenetic states and contribute to changes in gene expression. Overall, there is a complex interplay between genetics, epigenetics, and environment, which can influence gene expression. In this review, we will focus on DNA methylation, one of the first epigenetic modifications to be well characterized, especially through genome-wide assays, and outline its role in the pathogenesis of diabetes.
| DNA METHYLATION AND ITS ROLE IN THE REGULATION OF GENE EXPRESSION
DNA methylation in mammalian cells typically involves covalent addition of a methyl group (-CH 3 ) at the 5 0 position of the cytosine ring within the 5 0 -CpG-3 0 dinucleotides to create a 5-methylcytosine (5-mC). 14 CpG sites tend to cluster together as repetitive sequences called as CpG islands (CpGI) found either at promoters of genes, or regions with increased centromeric tandem repeat units. 15 In humans, approximately 70% CpG dinucleotides are methylated, whereas CpG dinucleotides found at CpGI in germ-line tissues and those located near promoters of somatic cells mostly remain unmethylated. 15 In order for a gene to be transcribed, the promoter and other regulatory regions of the gene including enhancers must be accessible to transcription factors and other regulatory complexes. DNA methylation decreases accessibility of the DNA and can block the binding of transcription factors, thus affecting gene expression ( Figure 1A ). In fact, there is evidence that changes in CpG density and methylation status at tissue-specific promoters play an important role in controlling the expression of the associated genes. 16 In addition, specific histone modifications such as methylation of lysine residues in the amino termini of histone 3 (H3), or removal of acetyl groups from lysine residues on histones H3 and H4 by histone deacetylases can alter the conformation of the chromatin, resulting in a more condensed chromatin form thus restricting access of the transcription factors. 15 Regions with condensed inaccessible chromatin structures and methylated CpG sites with associated low rates of mRNA transcription are called heterochromatin ( Figure 1B) . 15 In contrast, open and active chromatin structures with locally unmethylated
CpGs that are associated with high rates of transcription and are referred to as euchromatin ( Figure 1B ). ultimately affecting the expression of genes during development and differentiation. [25] [26] [27] In addition, DNA methylation in CpGI plays a critical role in establishing imprinting marks, 28, 29 while DNA methylation in the gene body is associated with altered gene expression in dividing cells. [30] [31] [32] Genomic imprinting is the epigenetic phenomena when genes are expressed based on parent of origin of the allele.
Changes in DNA methylation resulting from genomic imprinting have been linked to 6q24 transient neonatal diabetes, 33 where patients with transient neonatal diabetes have decreased methylation of the maternal allele at the 6q24 locus. 34, 35 In these patients, diabetes resolves after several months of life; however, the underlying mechanism remains to be completely elucidated.
| METHODS FOR DETECTING GENOME-WIDE AND SITE-SPECIFIC DNA METHYLATION.
Currently, various techniques have been developed to determine site-specific and genome-wide changes in DNA that associate with changes in gene expression and can be used as markers for risk assessment, early prognosis, and treatment of disease.
In this section, we describe techniques used to measure DNA methylation both at specific sites within the genome and assays that measure DNA methylation on a genome-wide scale.
| Methods for detecting site-specific DNA methylation
Most site-specific DNA methylation techniques involve bisulfite conversion and are discussed below.
• Bisulfite pyrosequencing involves bisulfite treatment of genomic DNA where unmethylated cytosine residues of the DNA are converted to uracil, and methylated cytosines remain unmodified. This is followed by amplification of the bisulfite-converted product through polymerase chain reaction (PCR) where uracil is converted to thymine using site-targeted biotinylated primers.
Finally, successfully converted bisulfite PCR products are sequenced using specifically designed pyrosequencing primers. 36 The pyrogram gives percent methylation at each CpG site based on the number of unconverted C and converted T. Pyrosequecing offers sequencing of only short stretches of DNA, which limits the number of CpG sites that can be assessed by this technique. However, a potential benefit is that percent methylation at multiple CpG sites (though few in number) can be accurately quantified in one reaction.
• Methylation sensitive PCR (MSP) involves use of bisulfiteconverted DNA followed by PCR with primers-specific for methylated vs unmethylated DNA. 37 
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• Bisulfite treatment followed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) uses bisulfite-converted DNA, followed by PCR primers using primers with T7 RNA polymerase tag 40 and the products are translated into a single-stranded RNA using T7 polymerase, followed by cleavage by an endoribonuclease such as RNase A. The methylated and unmethylated CpGs generate different cleavage patterns which are then quantitated by mass spectrometry. 40 Unlike pyrosequencing, this technique covers wider stretch of DNA and therefore multiple CpG sites can be detected in one reaction. However, the technical complexity of this method makes it less user friendly.
| Methods for detecting genome-wide DNA methylation
• Methylated DNA Immunoprecipitation (MeDIP) and Methyl-CpG binding domain (MBD) protein capture are two commonly used approaches to enrich for methylated DNA regions of the genome which can undergo further analysis with sequencing to detect differentially methylated CpG sites. 41 MeDIP uses a monoclonal antibody specific to 5 0 -methylcytosine to immunoprecipitate single-stranded DNA containing 1 or more CpG sites, 42 while the MBD uses the methyl-CpG binding domain of the MBD2 protein to capture double-stranded methylated DNA fragments and differentiates variable DNA methylation densities by using different salt concentrations during the elution step. 43 One potential drawback of these methods is that the density of methylated cytosines in a particular region of DNA can affect the antibody binding. 41 From findings in the literature, it is suggestive that MeDIP is more effective for enriching methylated areas with low CpG density, while MBD protein capture with high, CpG density.
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• Luminometric methylation assay (LUMA) uses methylation sensitive and insensitive restriction enzymes to digest genomic DNA, followed by quantifying the resulting number of cuts from the restriction enzymes using a pyrosequencer. 44, 45 As LUMA is unable to identify specific positions in the genome where methylation is located it represents global methylation analysis.
• 47 This technique uses low input sample amount (as low as 250 ng) and is reported to be highly reproducible. 47 Its moderate cost for genome-wide DNA methylation analysis permits for larger number of samples needed for studies of human samples. Thus, by offering a comprehensive genome-wide DNA methylation analysis, MethylationEPIC is a promising technique to assess genome-wide DNA methylation pattern.
• Enhanced reduced representation bisulphite sequencing (ERRBS) involves digestion of 10-300 ng of purified genomic DNA using methylation-insensitive restriction enzyme (commonly MspI), followed by end repair, A-tailing, adapter ligation, size selection, bisulfite conversion, and PCR amplification. 48, 49 The prepared libraries are then sequenced and analyzed to determine differentially methylated sites. This assay is designed to target CpG dense promoter regions and repeated elements, which helps to control the high cost of sequencing the entire genome. This technique effectively captures 3 million CpG sites including 85% of CpG islands, and 60% promoters. 49 Therefore, ERRBS provides a reasonable and cost effective method to measure genome-wide DNA methylation.
• Whole-genome bisulfite sequencing (WGBS) uses 50-100 ng of purified genomic DNA for library preparation that entails fragmentation of the DNA to generate 3 0 or 5 0 overhangs using an ultrasonicator, followed by end repair, adenylation of 3 0 ends, and adaptor ligation. followed by next-generation sequencing. [50] [51] [52] [53] As this technique involves sequencing of the entire genome, it is not very cost effective. However, with declining cost of WGBS, this method will become a critical tool for detecting changes in DNA methylation, especially within intergenic regions and enhancers which have been shown to be key regulatory regions in islets from patients with T2DM and CD34 cells exposed to intra-uterine growth restriction. 54 Neither the array-based genome-wide DNA methylation assays nor ERRBS adequately profile DNA methylation within the intergenic and enhancer regions of the genome. Table 1 provides a summary of few genome-wide DNA methylation techniques that are discussed above.
| ROLE OF DNA METHYLATION IN DEVELOPMENTAL ORIGINS OF DIABETES
The period from conception to birth is a time of rapid growth, cellular In this section, we will cover some of the DOHaD models that have indicated alterations in DNA methylation specifically in context of T2DM.
| IUGR models
Exposure to IUGR has profound effects on the expression of genes that control glucose and energy homeostasis in pancreatic islets and peripheral tissues (liver, skeletal muscle, and adipose tissue). The following studies indicate that DNA methylation is one mechanism by which an in utero insult can lead to the development of diabetes in adult offspring.
| Maternal nutrient deprivation (protein restriction) model and DNA methylation
Various studies have shown that maternal diet can induce changes in the heritable epigenome, which would influence the later metabolic health of the offspring. Sandovici et al found reduced expression of the pancreatic transcription factor Hnf4α in rat islets from offspring of mothers who were fed a low protein diet. 58 In this model, reduced expression of Hnf4α was associated with increased DNA methylation at P2 promoter, along with reduced activating histone modifications, and increased silencing histone modifications at 3 months of age. 58 These studies demonstrate that a maternal suboptimal nutrient environment influenced the epigenetic state of Hnf4α, which consequently lead to changes in Hnf4α expression. Similarly, maternal low protein diet has been shown to influence locus-specific epigenetic changes, including the liver X-receptor alpha promoter and target genes like Abcg5/Abcg8, as well as global DNA methylation in offspring liver. [59] [60] [61] Other studies have shown that exposure to a maternal low protein diet along with folic acid supplementation result in changes in DNA methylation at the Pparα and glucocoticoid receptor (GR) promoter and corresponding changes in gene expression in liver from juvenile and adult rat offspring. 62, 63 Furthermore, from fetal life to adulthood the offspring of dams fed a low protein diet had altered methylation levels in leptin promoter in adipose tissue, and this was associated with altered feeding behavior in the offspring. 64 Therefore, in utero nutritional perturbations can lead to changes in DNA methylation that have lifelong effects on the metabolic health of the offspring.
| Uterine artery ligation model and DNA methylation
Uterine bilateral artery ligation is another model of inducing IUGR, and animals generated via this technique experience in utero placental insufficiency (UPI) and go on to develop T2DM in adulthood. 65 Epige- proximal Pdx1 promoter and initiation of de novo DNA methylation leading to permanent reduction of Pdx1 gene expression in adulthood. 67 Altered genome-wide DNA methylation in the IUGR model was described by Thompson et al who found 1400 differentially methylated loci in isolated islets from adult male rats exposured to IUGR. 68 A majority of the differentially methylated CpG sites were found at conserved intergenic regions, and near genes that had been previously described as key regulators of important β-cell processes like cell division and death, vascularization, and insulin secretion. 68 Thus, perturbed DNA methylation in UPI model appears to be an important epigenetic mechanism involved in regulating β-cell development and function.
| Exposure to endocrine disrupting chemicals model and DNA methylation
Unlike the in utero caloric restriction nutritional model where imprinted genes were reported to be unaffected, 69 exposure to endocrine disrupting chemicals such as BPA has been shown to affect the expression of imprinted genes. In this context, prenatal exposure to BPA from 2 weeks prior to mating and throughout gestation, leads to loss of imprinting of Igf2 and gain of Igf2 gene expression in embryos. 70 Igf2 is expressed of the paternal allele, and loss of Igf2 imprinting leads to increased expression of Igf2 through both maternal and paternal alleles. This occurs because of an increase on DNA methylation in Igf2 differentially methylated region 1 (DMR1), which is normally unmethylated. A repressor protein, GCF2, binds to unmethylated DMR1, and blocks enhancer access to Igf2. 71 The methylation of DMR1 prevents GCF2 binding and permits enhancerIgf2 interaction, leading to Igf2 expression. 71 In utero exposure to BPA in mice increases Igf2 DMR1 methylation and Igf2 expression from both maternal and paternal allele in embryos. 70 While Igf2 has many other roles, it is a key regulator of early β-cell development in islets and aberrant Igf2 imprinting early in life could potentially influence the normal β-cell development. However, whether increased Igf2 expression is the mechanism underlying the impaired glucose tolerance reported in these animals is currently under investigation. 
| Gestational diabetes mellitus and DNA methylation
Population-based studies demonstrate that the offspring of diabetic mothers have an increased risk for obesity, glucose intolerance, and T2DM. 73, 74 It has been proposed that early exposure to hyperglycemia and elevated insulin levels may lead to a malprogramming of critical functions related to the development of diabetes and obesity later in life. 75 Several studies have sought to identify changes in genome-wide DNA methylation resulting from exposure to GDM as one mechanism contributing to the malprogramming of the offspring. [73] [74] [75] Various studies have mapped genome-wide DNA methylation using the Infinium 450K bead array or MeDIP in placentae from women with GDM and have found increased number of differentially methylated genes predominantly involved in glucose metabolism pathway and in energy metabolism. RNA-Seq data and protein levels (under review). They report that placentae from female offspring exposed to GDM were 40% more likely to have significant gains in DNA methylation compared to placentae from male offspring. In addition, changes in DNA methylation corresponded to changes in mRNA expression and protein levels in Piwil3, Cyba, Gstm1, Gstm5, Kcne1, and Nxn. Systems-based analysis showed that in utero exposure to GDM lead to significant alterations in DNA methylation in genes related to mitochondrial function, DNA repair, inflammation, and oxidative stress. Together, these studies indicate that in utero exposure to GDM can alter DNA methylation on a genome-wide basis and that some of the changes in DNA methylation induced by exposure to GDM are followed by corresponding changes in gene expression.
| T2DM, ISLETS, AND DNA METHYLATION
Impaired insulin secretion by the pancreatic islet is a key component to the pathogenesis of T2DM. Therefore, several studies have used a candidate gene approach to study the relationship between changes in DNA methylation and gene expression in islets from donors with T2DM. Increased DNA methylation was measured CpG sites within the promoters of the pancreatic transcription factor Pdx1, the mitochondrial gene regulator Ppargc1a and Ins gene, which negatively correlated with mRNA expression in all 3 genes. [80] [81] [82] Using the genomewide Infinium 450K array, 1649 CpG sites, and 853 genes, including Tcf7l2, Fto, Kcnq1, Irs1, Cdkn1a, and Pde7b were identified to have significant changes in DNA methylation in human islets from T2DM donors compared to controls. 83 Of the 853 genes with differentially methylated CpG sites, 102 genes, including Cdkn1a, Pde7b, Sept9, and Exoc3l2, had significant changes in mRNA expression as measured by microarray. 83 Increased DNA methylation at the promoter of Cdkn1a and Pde7b was associated with decreased transcriptional activity in clonal β-cells in vitro as well as impaired glucose stimulated insulin secretion. 83 Another genome-wide study of DNA methylation using the Infinium 27K array found 276 differentially methylated CpG sites of which 96% were hypomethylated in islets of diabetic vs non-diabetic donors. 84 Changes in differential DNA methylation were correlated with expression changes of 34 genes assessed by microarray. 84 The changes in DNA methylation identified in islets from T2DM were not found in DNA from peripheral blood from T2DM donors nor were these induced by exposing a clonal β-cell line to hyperglycemia. 85 These studies indicate that alterations in DNA methylation could be a potential mechanism contributing to the pathogenesis of T2DM in the islets.
While changes in islet DNA methylation are linked to T2DM, changes in DNA methylation associated with peripheral insulin resistance may also increase the risk of T2DM. In this review, we focused on studies assessing changes in DNA methylation in islets; changes in DNA methylation at peripheral tissues such as liver, muscle, and adipose and their association with diabetes are reviewed elsewhere. 86, 87 Some changes in DNA methylation in peripheral tissues have been shown to be amenable to modification by simple physiological interventions like exercise. For example, a 6 months exercise intervention induced noticeable alterations in genome-wide DNA methylation profile and gene expression in adipose tissue of obese and type 2 diabetic patients. 88 Similarly, 3 months exercise program was associated with DNA methylation and gene expression changes in skeletal tissue of non-diabetic male and female volunteers. 89 Results from these studies indicate that changes in DNA methylation may not be permanent and in fact may represent key targets of intervention in future studies.
| T1DM, ISLETS, IMMUNE CELLS, AND DNA METHYLATION
In monozygotic twin pairs, only 50% co-twins develop T1DM 90 93 Epigenetic changes are challenging to interpret in a mixed cell population such as whole blood because these changes may reflect differences in white blood cell populations, which may or may not be related to a disease phenotype.
Recently, a study highlighted the cross talk between immune responses and β-cell-specific DNA methylation changes at Ins1 and Ins2 in islets from Non-obese diabetic (NOD) mice, and in human β-cells in vitro. 94 In the NOD mouse model of T1DM, inflammatory cytokines including TNF, IFNγ, IL6, and IL1B increase with age. 94 Rui et al showed reduced insulin gene expression and increased percent DNA methylation at exon 2 of Ins1 and exon 1 of Ins2 genes in sorted β-cells from 4-week-old NOD mice cultured in media with cytokines. 94 Moreover, increased cytokines induced mRNA expression levels of DNMTs in sorted β-cells of cultured islets from NOD mice and from human non-diabetic donors. 94 This study suggests that increased cytokine levels associated with T1DM induce increased DNA methylation and decreased insulin mRNA levels in islets.
Recently, there has been interest in quantifying the amount unmethylated preproinsulin DNA in the circulation as a biomarker of β-cell death. β-cells have a much higher frequency of unmethylated CpG sites within the preproinsulin DNA sequence than other cells, and upon β-cell death these DNA sequences are released into the circulation. 95 Studies have found increased levels of unmethylated preproinsulin DNA in peripheral blood samples of patients with new-onset T1DM compared with controls. 96, 97 In addition, a recent study by
Belot et al found decreased DNA methylation at the imprinted gene RTL1 in peripheral whole blood DNA from patients recently diagnosed with T1DM. 98 These findings suggest that RTL1 methylation status could be used to identify patients who may be good candidates for β-cell preservation therapies currently in development for patients with T1DM.
| DIABETIC NEPHROPATHY AND DNA METHYLATION
The studies highlighted above focus on evidence that DNA methylation is associated with the pathogenesis of diabetes, but there is also evidence that changes in DNA methylation can be induced by hyperglycemia and other metabolic byproducts of diabetes which contribute to the development of diabetic complications in peripheral organs. 99 In addition, DNA methylation assays in peripherally accessi- 
| CONCLUSION AND FUTURE DIRECTIONS
Diabetes is an increasing health concern worldwide and a substantial 
